$ORKA
Oruka Therapeutics, Inc.

2015 Q1 Form 10-Q Financial Statement

#000156459015004080 Filed on May 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1 2014
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.040M $1.080M $4.070M
YoY Change -3.7% 21.48% 1.5%
% of Gross Profit
Research & Development $1.710M $1.310M $5.625M
YoY Change 30.53% 627.78% 91.98%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $10.00K
YoY Change -100.0% -61.54%
% of Gross Profit
Operating Expenses $2.744M $2.390M $9.693M
YoY Change 14.81% 168.84% 39.67%
Operating Profit -$2.744M -$2.390M -$9.693M
YoY Change 14.81% 123.36%
Interest Expense $1.000K $1.000K $3.000K
YoY Change 0.0% -25.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.740M -$2.389M -$9.690M
YoY Change 14.69% 123.06% 39.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.744M -$2.389M -$9.689M
YoY Change 14.86% 123.06% 39.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$16.12M -$15.93M -$60.56M
COMMON SHARES
Basic Shares Outstanding 18.79M 20.50M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q1 2014
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.20M $21.20M $15.40M
YoY Change -42.45% 505.71% -8.33%
Cash & Equivalents $12.18M $21.20M $15.40M
Short-Term Investments
Other Short-Term Assets $500.0K $600.0K $100.0K
YoY Change -16.67% 20.0% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.70M $21.80M $15.50M
YoY Change -41.74% 445.0% -8.28%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $800.0K $600.0K
YoY Change -25.0% 700.0% 500.0%
Total Long-Term Assets $600.0K $900.0K $600.0K
YoY Change -33.33% 800.0% 200.0%
TOTAL ASSETS
Total Short-Term Assets $12.70M $21.80M $15.50M
Total Long-Term Assets $600.0K $900.0K $600.0K
Total Assets $13.30M $22.70M $16.10M
YoY Change -41.41% 453.66% -5.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $600.0K $800.0K
YoY Change 16.67% 50.0% 33.33%
Accrued Expenses $500.0K $600.0K $600.0K
YoY Change -16.67% 50.0% -33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.100M $1.100M $1.400M
YoY Change 0.0% 37.5% -6.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.100M $1.100M $1.400M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.100M $1.121M $1.400M
YoY Change -1.87% 40.13% -6.67%
SHAREHOLDERS EQUITY
Retained Earnings -$77.32M
YoY Change
Common Stock $21.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.10M $21.53M $14.70M
YoY Change
Total Liabilities & Shareholders Equity $13.30M $22.66M $16.10M
YoY Change -41.29% 452.56% -5.85%

Cashflow Statement

Concept 2015 Q1 2014 Q1 2014
OPERATING ACTIVITIES
Net Income -$2.744M -$2.389M -$9.689M
YoY Change 14.86% 123.06% 39.63%
Depreciation, Depletion And Amortization $0.00 $0.00 $10.00K
YoY Change -100.0% -61.54%
Cash From Operating Activities -$3.110M -$3.690M -$9.410M
YoY Change -15.72% 382.98% 77.95%
INVESTING ACTIVITIES
Capital Expenditures $2.000K $0.00 $19.00K
YoY Change -100.0% -40.63%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 -$20.00K
YoY Change -100.0% -37.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.018M $9.038M
YoY Change 417.98% 419.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -60.00K 8.130M 8.020M
YoY Change -100.74% 484.89% -58.13%
NET CHANGE
Cash From Operating Activities -3.110M -3.690M -9.410M
Cash From Investing Activities 0.000 0.000 -20.00K
Cash From Financing Activities -60.00K 8.130M 8.020M
Net Change In Cash -3.170M 4.440M -1.410M
YoY Change -171.4% 619.61% -110.19%
FREE CASH FLOW
Cash From Operating Activities -$3.110M -$3.690M -$9.410M
Capital Expenditures $2.000K $0.00 $19.00K
Free Cash Flow -$3.112M -$3.690M -$9.429M
YoY Change -15.66% 377.36% 77.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-9689000
CY2014Q1 us-gaap Interest Expense
InterestExpense
1000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
99342000
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
2744000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
2390000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2389000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21167523
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18785418
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
15581000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7866000
CY2014 abio Issuance Of Common Stock Upon Exercise Of Warrants For Cash Value
IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue
338000
CY2014 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-2000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
647000
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
130000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000
CY2015Q1 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
31000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
130000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
158000
CY2015Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
139000
CY2014Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
251000
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
698000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-144000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-45000
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-206000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-348000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-43000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-117000
CY2015Q1 us-gaap Increase Decrease In Other Current Assets And Liabilities Net
IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
2000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3113000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3687000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9018000
CY2015Q1 us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
55000
CY2014Q1 us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
51000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-55000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8133000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3170000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4446000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16756000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21202000
CY2015Q1 us-gaap Interest Paid
InterestPaid
1000
CY2014Q1 us-gaap Interest Paid
InterestPaid
1000
CY2015Q1 abio Vendor Finance Agreement
VendorFinanceAgreement
138000
CY2014Q1 abio Vendor Finance Agreement
VendorFinanceAgreement
128000
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p></div>
CY2015Q1 us-gaap Revenues
Revenues
0
CY2015Q1 abio Notification For Delisting Of Shares Description
NotificationForDelistingOfSharesDescription
On February 18, 2015, we received notification from Nasdaq of potential delisting of our shares from the Nasdaq Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. Nasdaq rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. In order to remain compliant with the Nasdaq listing standards, the Company expects to effect a reverse stock split of its common stock to increase the market price of the common stock above the Nasdaq minimum bid price listing standard. However, the effect of a reverse stock Split on the market price of the common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of the Company’s common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing the Company’s market capitalization, and there can be no assurance that the market price per post-reverse split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of the Company’s common stock may vary based on other factors that are unrelated to the number of shares outstanding, including the Company’s future performance.
CY2015Q1 abio Closing Bid Price Of Common Stock
ClosingBidPriceOfCommonStock
1.00
CY2015Q1 abio Grace Period Provided To Meet Continued Listing Standard
GracePeriodProvidedToMeetContinuedListingStandard
P180D
CY2015Q1 us-gaap Concentration Risk Credit Risk Financial Instrument Maximum Exposure
ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
0
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11188138
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11034321
CY2015Q1 abio Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
420000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
418000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
386000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
382000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
61000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
62000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
123000
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
20000
CY2014Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
19000
CY2015Q1 abio Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2015Q1 abio Expected Milestone Payments Upon Approval
ExpectedMilestonePaymentsUponApproval
8000000
CY2015Q1 abio Another Expected Milestone Payments Upon Approval
AnotherExpectedMilestonePaymentsUponApproval
5000000
CY2015Q1 abio Minimum Percentage Of Royalty Obligation
MinimumPercentageOfRoyaltyObligation
0.125
CY2015Q1 abio Maximum Percentage Of Royalty Obligation
MaximumPercentageOfRoyaltyObligation
0.25
CY2015Q1 abio Percentage Of Royalty Obligated To Pay Under Its Original License Agreement
PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement
0.05
CY2015Q1 abio Minimum Percentage Of Range Of Royalties That Can Be Buy Down
MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown
0.125
CY2015Q1 abio Maximum Percentage Of Range Of Royalties That Can Be Buy Down
MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown
0.17
CY2015Q1 abio Royalty Buy Down Due Period
RoyaltyBuyDownDuePeriod
P6M
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9371002
CY2015Q1 abio Weighted Average Exercise Price Of Warrants Or Rights
WeightedAverageExercisePriceOfWarrantsOrRights
2.31
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
130000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
158000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1068515
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
121780
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
183
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1190112
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
576567
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1188716
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.89
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.67
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.36
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.95
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.66
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M7D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M9D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
471029
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
203920
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
47925
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
627024
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.62
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.67
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.95
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.29

Files In Submission

Name View Source Status
0001564590-15-004080-index-headers.html Edgar Link pending
0001564590-15-004080-index.html Edgar Link pending
0001564590-15-004080.txt Edgar Link pending
0001564590-15-004080-xbrl.zip Edgar Link pending
abio-10q_20150331.htm Edgar Link pending
abio-20150331.xml Edgar Link completed
abio-20150331.xsd Edgar Link pending
abio-20150331_cal.xml Edgar Link unprocessable
abio-20150331_def.xml Edgar Link unprocessable
abio-20150331_lab.xml Edgar Link unprocessable
abio-20150331_pre.xml Edgar Link unprocessable
abio-ex101_20150331151.htm Edgar Link pending
abio-ex311_201503316.htm Edgar Link pending
abio-ex312_2015033110.htm Edgar Link pending
abio-ex321_201503317.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201505121605432902547.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending